射血分数保留的心力衰竭药物治疗对结局的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入25项随机对照试验共18101例左心室射血分数≥40%的心力衰竭患者,评估各类药物对全因死亡等结局的影响。结果显示β受体阻滞剂较安慰剂降低全因死亡率(RR 0.78,95%CI 0.65-0.94,p=0.008),而ACE抑制剂、醛固酮受体拮抗剂等未显示获益,且无单个药物类别降低心衰住院。
要点
- β受体阻滞剂较安慰剂降低全因死亡率(RR 0.78,95%CI 0.65-0.94,p=0.008)。
- ACE抑制剂、醛固酮受体拮抗剂等未显示降低全因死亡率。
- 无单个药物类别较安慰剂降低心衰住院。
核心结论
- 在左心室射血分数≥40%的心衰患者中,β受体阻滞剂较安慰剂降低全因死亡率和心血管死亡率,其他药物类别未见此效应。
研究设计与样本
- 系统检索Medline、Embase和Cochrane Central Register of Controlled Trials(1996年1月至2016年5月)的随机对照试验,纳入25项RCT共18101例左心室射血分数≥40%的心衰患者。
主要发现
- β受体阻滞剂较安慰剂降低全因死亡率(RR 0.78,95%CI 0.65-0.94,p=0.008)。
- ACE抑制剂、醛固酮受体阻滞剂、盐皮质激素受体拮抗剂及其他药物类别较安慰剂未见全因死亡率效应。
- 心血管死亡率结果与全因死亡率相似。
- 无单个药物类别较安慰剂降低心衰住院。
临床怎么用
- 对于左心室射血分数≥40%的心衰患者,可考虑使用β受体阻滞剂以降低全因和心血管死亡风险。
局限性
- 需进一步试验确认β受体阻滞剂在该患者群体中的治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical drug trials in patients with heart failure and preserved ejection fraction have failed to demonstrate improvements in mortality. METHODS: We systematically searched Medline, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCT) assessing pharmacological treatments in patients with heart failure with left ventricular (LV) ejection fraction≥40% from January 1996 to May 2016. The primary efficacy outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure hospitalisation, exercise capacity (6-min walk distance, exercise duration, VO2 max), quality of life and biomarkers (B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide). Random-effects models were used to estimate pooled relative risks (RR) for the binary outcomes, and weighted mean differences for continuous outcomes, with 95% CI. RESULTS: We included data from 25 RCTs comprising data for 18101 patients. All-cause mortality was reduced with beta-blocker therapy compared with placebo (RR: 0.78, 95%CI 0.65 to 0.94, p=0.008). There was no effect seen with ACE inhibitors, aldosterone receptor blockers, mineralocorticoid receptor antagonists and other drug classes, compared with placebo. Similar results were observed for cardiovascular mortality. No single drug class reduced heart failure hospitalisation compared with placebo. CONCLUSION: The efficacy of treatments in patients with heart failure and an LV ejection fraction≥40% differ depending on the type of therapy, with beta-blockers demonstrating reductions in all-cause and cardiovascular mortality. Further trials are warranted to confirm treatment effects of beta-blockers in this patient group.
引用
- Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017. PMID: 28780577. doi:10.1136/heartjnl-2017-311652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。